Xavier Ansolabehere
Xavier Ansolabehere publishes mostly in Endocrinology, Diabetes and Metabolism, Immunology and Allergy and Pulmonary and Respiratory Medicine, on topics such as Allergic Rhinitis and Sensitization, Dermatology and Skin Diseases and Diabetes Treatment and Management.
- World rank
- #5,412,357 of 7,710,434 ranked researchers
- Rank in France
- #229,101 of 324,115
- Works
- 28
- Citations
- 131
- Citations per work
- 4.7
What does Xavier Ansolabehere research?
Xavier Ansolabehere's work is mostly in Medicine (48%), Economics, Econometrics and Finance (9%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1347.5%
- Medicine1347.5%
- Everything else1243.5%
- Social Sciences39.0%
- 1Endocrinology, Diabetes and Metabolism14% of their works
- 2Immunology and Allergy10% of their works
- 3Pulmonary and Respiratory Medicine10% of their works
- 4Economics and Econometrics9% of their works
- 5Dermatology8% of their works
- 6Epidemiology5% of their works
Research topics
- Allergic Rhinitis and Sensitization
- Dermatology and Skin Diseases
- Diabetes Treatment and Management
- Gout, Hyperuricemia, Uric Acid
- Asthma and respiratory diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Systems, Economic Evaluations, Quality of Life
- Systemic Sclerosis and Related Diseases
Which keywords describe Xavier Ansolabehere's research?
The keywords of their largest research topics: Asthma, Quality of Life, Inflammation, Endothelial Dysfunction, Fibrosis, Treatment, Allergen-specific Immunotherapy and Pollen Allergy.
- Systemic Sclerosis
- Uric Acid
- Skin Microbiome
- Idiopathic Pulmonary Fibrosis
- Health Utility Measures
- Eosinophils
- Cardiovascular Outcomes
- Pollen Allergy
- Treatment
- Endothelial Dysfunction
- Quality of Life
- Asthma
- Inflammation
- Fibrosis
- Allergen-specific Immunotherapy
- Allergic Diseases
- Cost-effectiveness Analysis
- Filaggrin
- Hyperuricemia
- Interstitial Lung Disease
- Type 2 Diabetes
- Autoantibodies
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Asthma102 topics
- Quality of Life102 topics
- Inflammation82 topics
- Endothelial Dysfunction72 topics
- Fibrosis72 topics
- Treatment72 topics
- Allergen-specific Immunotherapy61 topic
- Pollen Allergy61 topic
- Allergic Diseases41 topic
- Cardiovascular Outcomes41 topic
- Cost-effectiveness Analysis41 topic
- Eosinophils41 topic
- Filaggrin41 topic
- Health Utility Measures41 topic
- Hyperuricemia41 topic
- Idiopathic Pulmonary Fibrosis41 topic
- Interstitial Lung Disease41 topic
- Skin Microbiome41 topic
- Type 2 Diabetes41 topic
- Uric Acid41 topic
- Autoantibodies31 topic
- Systemic Sclerosis31 topic
Where does Xavier Ansolabehere work?
Xavier Ansolabehere's main affiliation in the publication record is Institut Polytechnique de Bordeaux, France.
How many publications and citations does Xavier Ansolabehere have?
OpenAlex counts 28 works and 131 citations for Xavier Ansolabehere, an h-index of 6, ranking #5,412,357 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Xavier Ansolabehere. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.